Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
Keywords:
bcl-2, Prostate, Prostate adenocarcinoma, ApoptosisAbstract
CONTEXT: Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. The major difficulty is in that the clinical management stems from the reality that reliable and accurate prognostic biomarkers are not available and that effective treatment regimens forming hormone-resistant prostate cancers are yet to be developed. Among the most important regulators of apoptosis and programmed cell death is the bcl-2 gene and its related proteins. Elevated levels of bcl-2 protein may contribute to the progression of prostate cancers to a metastatic and hormone-insensitive state characterized by poor responses to chemotherapy. OBJECTIVE: To characterize the expression of bcl-2 proteins as a prognostic factor in humans. DESIGN: A retrospective approach. SETTING: Urology section, Federal University of São Paulo. DIAGNOSTIC TEST USED: Immunohistochemical analysis using bcl-2 protein antibody and normal staining by hematoxylin-eosin. MAIN MEASUREMENTS: Prognostic relations and protein expression were evaluated considering the total sample (28) divided into two groups, high (8 to 10) and low (2 to 4), separated according to the histological differentiation grade (Gleason score) with 10 and 18 samples, respectively. RESULTS: The differentiation of grade into two groups separated according to the Gleason score in low and high types presented different bcl-2 expression (P < 0.001). CONCLUSION: The higher frequency of bcl-2 immunostaining in tumor samples was observed in association with more advanced Gleason scores and suggests that an increase in the ratio of this anti-apoptotic protein often occurs during progression of prostate cancers.
Downloads
References
Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X and mcl-1 expression in pros- tate cancer. Am J Pathol 1996;148:1567-76.
McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52;6940-4.
Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997;32:284-93.
Raffo AJ, Perlman H, Chen MW, et al. Over-expression of bcl- 2 protects cancer cells from apoptosis in vitro and confers re- sistance to androgen depletion in vivo. Cancer Res 1995;55:4438:45.
Hockenbery DM. The bcl-2 oncogene and apoptosis. Semin Immunol 1992;4:413-20.
Lipponen P, Vesalainen S. Expression of the apoptosis-suppress- ing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy. Prostate 1997;32:9-15.
Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: New implications for therapy. Blood 1993;82:15-21.
Doglioni C, Dei Tos AP, Laurino L, et al. The prevalence of bcl- 2 immunoreactivity in breast carcinomas and its clinicopatho- logical correlates, with particular reference to oestrogen receptor status. Virchows Arch 1994, 47-51.
Wyllie AH. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview. Cancer Metastat Rev 1992;11:95-103.
Lipponen P, Pietilainen T, Kosma V-M, et al. Apoptosis-sup- pressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favorable prognosis. J Pathol 1995;177:49-55.
Lu QL, Poulson R, Wong L, Hanby AM. bcl-2 expression in adult and embryonic non-hematopoietic tissues. J Pathol 1993;169:431-7.
Visakorpi T, Kallioniemi O-P, Heikkinen A, et al. Small subgroup of aggressive highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992;84:883-7.
Colombel M, Symmans F, Gil S, et al. Detection of apoptosis- suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer. Am J Pathol 1993;143:390-400.
Reed JC. bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
Lipponen P, Aaltoma S. Apoptosis in bladder cancer as related to standard prognostic factor and prognosis. J Pathol 1994;173: 333-40.
Westin P, Stattin P, Damber JE, Berg A. Castration therapy rap- idly induces apoptosis in a minority and decreases cell prolif- eration in a majority of human prostatic tumors. Am J Pathol 1995;146:1368-75.
Tsuji M, Murakami Y, Kanayama H, et al. Immunohistochemi- cal analysis of Ki-67 antigen and bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy. Br J Urol 1998;81:116-21.
McConkey DJ, Greene G, Pettaway LA. Apoptosis resistance increases with metastatic potential in cells of the human LNCap prostate carcinoma line. Cancer Res 1996;56:5594-9.
Grossfeld GD, Olumi AF, Connolly JA, et al. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol; 1998, 159:1437-43.
